drugset
drugset / Trial / NCT01697605

A Phase I Study of Oral BGJ398 in Asian Patients

NCT01697605 ↗

Phase 1 Completed 9 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate safety and tolerability to determine the Maximum tolerated dose (MTD) and/or Recommended dose (RD).

Timeline

Start
2012-10-19
Primary completion
2019-02-07
Completion
2019-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Infigratinib Small molecule — Oral

Indications

No indication recorded.